-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Verve Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2020 to Q3 2024.
- Verve Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $10.8M, a 22.6% increase year-over-year.
- Verve Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $42.1M, a 29.1% increase year-over-year.
- Verve Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $35.1M, a 56.2% increase from 2022.
- Verve Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $22.5M, a 218% increase from 2021.
- Verve Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $7.07M, a 732% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)